236 related articles for article (PubMed ID: 30587545)
41. A SMAD4-modulated gene profile predicts disease-free survival in stage II and III colorectal cancer.
Szeglin BC; Wu C; Marco MR; Park HS; Zhang Z; Zhang B; Garcia-Aguilar J; Beauchamp RD; Chen XS; Smith JJ
Cancer Rep (Hoboken); 2022 Jan; 5(1):e1423. PubMed ID: 34114372
[TBL] [Abstract][Full Text] [Related]
42. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
[TBL] [Abstract][Full Text] [Related]
43. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study.
Alwers E; Jansen L; Bläker H; Kloor M; Tagscherer KE; Roth W; Boakye D; Herpel E; Grüllich C; Chang-Claude J; Brenner H; Hoffmeister M
Mol Oncol; 2020 Feb; 14(2):363-372. PubMed ID: 31816156
[TBL] [Abstract][Full Text] [Related]
44. Smad4 may help to identify a subset of colorectal cancer patients with early recurrence after curative therapy.
Ahn BK; Jang SH; Paik SS; Lee KH
Hepatogastroenterology; 2011; 58(112):1933-6. PubMed ID: 22024061
[TBL] [Abstract][Full Text] [Related]
45. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
46. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
[TBL] [Abstract][Full Text] [Related]
47. The adaptive immune response to colorectal cancer: from the laboratory to clinical practice.
Curtis NJ; Primrose JN; Thomas GJ; Mirnezami AH; Ottensmeier CH
Eur J Surg Oncol; 2012 Oct; 38(10):889-96. PubMed ID: 22721580
[TBL] [Abstract][Full Text] [Related]
48. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
[TBL] [Abstract][Full Text] [Related]
49. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer.
Criscitiello C; Vingiani A; Maisonneuve P; Viale G; Viale G; Curigliano G
Breast Cancer Res Treat; 2020 Sep; 183(2):347-354. PubMed ID: 32621251
[TBL] [Abstract][Full Text] [Related]
50. Tumor budding as a predictive marker for 5-fluorouracil response in adjuvant-treated stage III colorectal cancer.
Akabane S; Shimizu W; Takakura Y; Kochi M; Taguchi K; Nakashima I; Sato K; Hattori M; Egi H; Sentani K; Yasui W; Ohdan H
Int J Clin Oncol; 2021 Jul; 26(7):1285-1292. PubMed ID: 33881678
[TBL] [Abstract][Full Text] [Related]
51. Systemic Chemotherapy for Metastatic Colitis-Associated Cancer Has a Worse Outcome Than Sporadic Colorectal Cancer: Matched Case Cohort Analysis.
Yaeger R; Paroder V; Bates DDB; Capanu M; Chou J; Tang L; Chatila W; Schultz N; Hersch J; Kelsen D
Clin Colorectal Cancer; 2020 Dec; 19(4):e151-e156. PubMed ID: 32798155
[TBL] [Abstract][Full Text] [Related]
52. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
[TBL] [Abstract][Full Text] [Related]
53. Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer.
Sawada K; Nakamura Y; Yamanaka T; Kuboki Y; Yamaguchi D; Yuki S; Yoshino T; Komatsu Y; Sakamoto N; Okamoto W; Fujii S
Clin Colorectal Cancer; 2018 Sep; 17(3):198-205. PubMed ID: 29866615
[TBL] [Abstract][Full Text] [Related]
54. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.
Deschoolmeester V; Baay M; Van Marck E; Weyler J; Vermeulen P; Lardon F; Vermorken JB
BMC Immunol; 2010 Apr; 11():19. PubMed ID: 20385003
[TBL] [Abstract][Full Text] [Related]
55. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
56. Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study.
Sgouros J; Aravantinos G; Kouvatseas G; Rapti A; Stamoulis G; Bisvikis A; Res H; Samantas E
J Gastrointest Cancer; 2015 Dec; 46(4):343-9. PubMed ID: 26143067
[TBL] [Abstract][Full Text] [Related]
57. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52.
Bolton JS; O'Connell MJ; Mahoney MR; Farr GH; Fitch TR; Maples WJ; Nagorney DM; Rubin J; Fuloria J; Steen PD; Alberts SR
Clin Colorectal Cancer; 2012 Mar; 11(1):31-7. PubMed ID: 21729678
[TBL] [Abstract][Full Text] [Related]
58. Loss of SMAD4 from colorectal cancer cells promotes CCL15 expression to recruit CCR1+ myeloid cells and facilitate liver metastasis.
Itatani Y; Kawada K; Fujishita T; Kakizaki F; Hirai H; Matsumoto T; Iwamoto M; Inamoto S; Hatano E; Hasegawa S; Maekawa T; Uemoto S; Sakai Y; Taketo MM
Gastroenterology; 2013 Nov; 145(5):1064-1075.e11. PubMed ID: 23891973
[TBL] [Abstract][Full Text] [Related]
59. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
60. The Effect of Perioperative Cimetidine Administration on Time to Colorectal Cancer Recurrence.
Ali AH; Hale L; Yalamanchili B; Ahmed M; Ahmed M; Zhou R; Wright SE
Am J Ther; 2018; 25(4):e405-e411. PubMed ID: 29630589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]